Legend Biotech Medical Affairs

We provide medical & scientific updates from Legend Biotech. Intended for US HCPs only. See pinned post for inquiries and community guidelines.

[Legend Biotech Medical Affairs @LegendUSMA]

At #EHA2026 Legend Biotech will have a late breaking oral presentation on the first in human trial of LB2501 dual targeting in vivo #CART. #lymsm

Click to read more: https://t.co/G16kJux4rH

[Legend Biotech Medical Affairs @LegendUSMA]

For US HCPs at #EHA2026, see Dr. Doris Hansen (@MoffittNews ) present data on real world evaluation of enterocolitis in BCMA CART treated patients.
#CART #mmsm

[Legend Biotech Medical Affairs @LegendUSMA]

For US HCPs at #EHA2026, see Dr. Samir Parekh present data on immune fitness and bone marrow tumor microenvironment from the CARTITUDE-4 study.
#CART #mmsm

[Legend Biotech Medical Affairs @LegendUSMA]

For US HCPs at #EHA2026, see Dr. Niels Van de Donk present data on CARTITUDE-4 cytogenic subgroup analysis.
#CART #mmsm

[Legend Biotech Medical Affairs @LegendUSMA]

Legend Biotech will be at #EHA2026. Find our medical team at booth A5.05. See you there!

[Legend Biotech Medical Affairs @LegendUSMA]

At #EHA2026 Legend Biotech will be presenting a Late-Breaking Oral Presentation for in vivo #CART. The presentation will be Sunday, June 14, 2026, 9:15-10:45 AM CEST.

Click the link to read more:
https://t.co/ryqk2kFpzl

[Legend Biotech Medical Affairs @LegendUSMA]

Thank you to those who joined us as #ASCO2026. We look forward to sharing more data at #EHA2026. #mmmsm #CART

[Legend Biotech Medical Affairs @LegendUSMA]

Announcing the New Legend Biotech sponsored ELITE Program. Grant Applications Open This Summer.

Contact your MSL for more information: https://t.co/cdTfwpR8Kx

[Legend Biotech @LegendBiotech]

#LegendNews at #EHA2026. We’ll present initial Phase 1 LB2501 data in relapsed/refractory B-cell NHL in a late-breaking oral presentation. The abstract highlights encouraging clinical activity and a favorable safety profile.

Learn more: https://t.co/1lTEqrcu00

@EHA_Hematology

[Legend Biotech Medical Affairs @LegendUSMA]

At #ASCO2026, Dr. Roberto Mina (@RobertoMinaMD ) of Emory University will present data from a cytogenetic subgroup analysis examining bridging therapy in CARTITUDE-4.
#CART #mmsm

[Legend Biotech Medical Affairs @LegendUSMA]

At #ASCO2026, Dr. Yi Lin (@YiLinMDPhD ) of the Mayo Clinic will present data on the incidence and characterization of Immune Effector Cell Associated Enterocolitis in the CARTITUDE clinical studies.
#CART #mmsm

[Legend Biotech Medical Affairs @LegendUSMA]

At #ASCO2026, Dr. Zhonglin Hao of the University of Kentucky will present preliminary results from an ongoing Phase 1 study of DLL3-targeted #CART in SCLC or LCNEC.

[Legend Biotech Medical Affairs @LegendUSMA]

Legend Biotech is live at #ASCO26! Stop by our booth to connect with the Legend Biotech Medical Affairs team and learn more about our latest research and initiatives. #mmsm

[Legend Biotech @LegendBiotech]

We’re at the @ASCO Annual Meeting this week. 👋

Attending? Swing by booth #21955 to learn more about how we’re advancing cell therapy in multiple myeloma and beyond. Also, check out our Heroes in Practice display honoring community oncologists.

#ASCO26 #CART #CellTherapy

[Legend Biotech Medical Affairs @LegendUSMA]

We’re heading to #ASCO in Chicago! Stop by the Legend Biotech booth to connect with our team. See you there! #ASCO2026

[Legend Biotech @LegendBiotech]

At #ASCO26, we’re bringing together members of the oncology community for an evening of conversation around the future of cell therapy, innovation, and what’s next in oncology.

📅 May 30
🕕 6:30-9:30 PM CT

For more information, contact your local MSL. https://t.co/RI1Q43Mo1F

[Legend Biotech @LegendBiotech]

#ASCO26 starts this week. We’ll be sharing new data across our CAR-T portfolio, including investigational findings in solid tumors and new analyses in multiple myeloma.

Stop by booth #21955 if you’re attending.

#CellTherapy

[Legend Biotech @LegendBiotech]

#LegendNews: Early LB2102 data in solid tumors will be presented at #ASCO26.

Additional data presented at @ASCO reinforce established efficacy and safety profile in #MultipleMyeloma.

Come find us at ASCO Booth #21955 to learn more and read more at: https://t.co/BZuAPKZwIF